Skip to main content
Fig. 1 | Trials

Fig. 1

From: The scientific rationale and study protocol for the DPP3, Angiotensin II, and Renin Kinetics in Sepsis (DARK-Sepsis) randomized controlled trial: serum biomarkers to predict response to angiotensin II versus standard-of-care vasopressor therapy in the treatment of septic shock

Fig. 1

Schedule of enrollment, interventions, and assessments. *Time zero is defined as 2 h after randomization in the standard of care arm and as time of angiotensin II initiation in the intervention arm. †Post-discontinuation biomarker levels will be obtained only in the angiotensin II arm. ‡See Data Collection Form for a full list of baseline characteristics/comorbidities/medical history, laboratory values, and adverse events being collected. §Acute kidney injury will be defined and staged using creatinine-based 2012 KDIGO (Kidney Disease Improving Global Outcomes) criteria [30]. ‖Diagnosis of ARDS will be ascertained via screening of clinical notes and corroborated by the investigators using the 2012 Berlin Criteria [31]. Abbreviations: DPP3, dipeptidyl-peptidase 3; ICU, intensive care unit; IMV, invasive mechanical ventilation; LOS, length of stay; KRT, kidney replacement therapy; SOFA, sequential organ failure assessment

Back to article page

Trials

ISSN: 1745-6215